Tarsus Pharmaceuticals, Inc. (TARS)
75.69
-0.27
(-0.36%)
USD |
NASDAQ |
Sep 25, 16:00
75.66
-0.02
(-0.03%)
After-Hours: 19:59
Tarsus Pharmaceuticals Enterprise Value : 2.914B for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 2.914B |
| September 24, 2026 | 2.926B |
| September 23, 2026 | 2.854B |
| September 22, 2026 | 2.974B |
| September 21, 2026 | 2.991B |
| September 18, 2026 | 3.018B |
| September 17, 2026 | 3.059B |
| September 16, 2026 | 2.999B |
| September 15, 2026 | 3.024B |
| September 14, 2026 | 3.099B |
| September 11, 2026 | 3.071B |
| September 10, 2026 | 3.149B |
| September 09, 2026 | 3.221B |
| September 08, 2026 | 3.413B |
| September 04, 2026 | 3.567B |
| September 03, 2026 | 3.239B |
| September 02, 2026 | 3.220B |
| September 01, 2026 | 2.843B |
| August 31, 2026 | 2.851B |
| August 28, 2026 | 2.744B |
| August 27, 2026 | 2.751B |
| August 26, 2026 | 2.696B |
| August 25, 2026 | 2.731B |
| August 24, 2026 | 2.790B |
| August 21, 2026 | 2.785B |
| Date | Value |
|---|---|
| August 20, 2026 | 2.732B |
| August 19, 2026 | 2.817B |
| August 18, 2026 | 2.713B |
| August 17, 2026 | 2.695B |
| August 14, 2026 | 2.633B |
| August 13, 2026 | 2.619B |
| August 12, 2026 | 2.669B |
| August 11, 2026 | 2.645B |
| August 10, 2026 | 2.571B |
| August 07, 2026 | 2.443B |
| August 06, 2026 | 2.466B |
| August 05, 2026 | 2.291B |
| August 04, 2026 | 2.283B |
| August 03, 2026 | 2.292B |
| July 31, 2026 | 2.194B |
| July 30, 2026 | 2.215B |
| July 29, 2026 | 2.171B |
| July 28, 2026 | 2.190B |
| July 27, 2026 | 2.240B |
| July 24, 2026 | 2.177B |
| July 23, 2026 | 2.174B |
| July 22, 2026 | 2.131B |
| July 21, 2026 | 2.117B |
| July 20, 2026 | 2.073B |
| July 17, 2026 | 2.229B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 162.41B |
| ANI Pharmaceuticals, Inc. | 1.935B |
| Corcept Therapeutics, Inc. | 12.23B |
| Veru, Inc. | 20.20M |
| Johnson & Johnson | 681.44B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.55M |
| Revenue (Quarterly) | 173.91M |
| Total Expenses (Quarterly) | 192.46M |
| EPS Diluted (Quarterly) | -0.4275 |
| Gross Profit Margin (Quarterly) | 93.04% |
| Profit Margin (Quarterly) | -10.67% |
| Earnings Yield | -1.43% |
| Normalized Earnings Yield | -1.428 |